Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Urology. 2019 Nov 11;136:169–175. doi: 10.1016/j.urology.2019.08.058

Table 1.

Baseline clinicopathological characteristics, stratified by histology

Clear Cell (n=139) Non-Clear Cell (n=53) p-value
Gender; Male (%) 116 (83.5) 37 (69.8) 0.045
Race (%) 0.167
Asian 6 (4.3) 0 (0.0)
Black 2 (1.4) 3 (5.7)
White 112 (80.6) 44 (83.0)
Unknown 19 (13.7) 6 (11.3)
BMI (median [IQR]) 26.60 [24.22, 30.71] 24.80 [21.92, 29.95] 0.075
Age (median [IQR]) 60.25 [51.82, 67.41] 58.67 [49.65, 63.89] 0.182
Smoking History; Yes (%) 77 (55.4) 26 (50.0) 0.519
No. of Metastatic Organs (median [IQR]) 2.00 [1.00, 3.00] 2.00 [1.00, 3.00] 0.528
Primary Tumor Stage (%) 0.474
T1 / T2 21 (14.5) 5 (9.4)
T3 / T4 118 (85.5) 48 (90.6)
Tumor Size (median [IQR]) 10.00 [8.00, 11.90] 9.40 [6.50, 14.00] 0.871
Node Status (%) 0.016
Involved 59 (42.4) 34 (64.2)
Nx 39 (28.1) 12 (22.6)
Not Involved 41 (29.5) 7 (13.2)
Pretreated; Yes (%) 11 (7.9) 3 (5.7) 0.761
KPS < 80 16 (14.4) 4 (9.8) 0.593